Cancer Drugs
Opdualag
Also known as: Nivolumab + Relatlimab, Anti–PD-1/LAG-3
Definition
A fixed-dose combination of nivolumab (PD-1) and relatlimab (LAG-3) used in advanced melanoma.
Detailed Explanation
Opdualag targets two checkpoints (PD-1 and LAG-3) to improve response in melanoma while aiming for lower toxicity than nivolumab + ipilimumab.